Just saw that BridgeBio wrapped up some pretty solid data from their Phase 3 FORTIFY trial for that rare muscle disorder treatment BBP-418. They just presented at the MDA conference last month and honestly the results look encouraging for LGMD2I/R9 patients. Katherine Mathews from Iowa gave the main talk, and they had Yale collaborators showing off their testing methods for measuring treatment response across different FKRP gene variants.

What caught my attention is how much groundwork they put into this - four poster sessions covering everything from disease burden to how the drug actually evolved from lab research to clinical trials. For a condition that's basically been ignored by most pharma companies, seeing this level of commitment to FORTIFY the evidence base is pretty refreshing. The company's really betting big on underserved genetic diseases where there's basically zero treatment options.

Stock-wise, BBIO has been bouncing around between $28 and $85 over the past year, closed at $66 last I checked. These clinical wins tend to matter for biotech plays, so could be worth keeping an eye on if you're into that space. The FORTIFY trial data definitely signals they're making real progress here.